CLOs on the Move

Hoveround Corporation

www.hoveround.com

 
Hoveround Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.hoveround.com
  • 2151 Whitfield Industrial Way
    Sarasota, FL USA 34243
  • Phone: 941.739.6200

Executives

Name Title Contact Details
Deb Silvers
Vice President of Corporate Compliance and General Counsel Profile

Similar Companies

Contract Pharmacy Services

Contract Pharmacy Services is a Warrington, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

angiomax

angiomax is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meditrina Inc

Meditrina, a small startup company located in San Jose, CA, and founded in 2016 developed the Aveta™ hysteroscopy suite which was designed to provide physicians with the best care in their diagnosis and treatment of endometrial polyps and uterine fibroids.

Amekam International

Amekam International is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.